Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

May 3, 2023
Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …

cdc-d5nff1slguy-unsplash

FDA approves Pfizer’s pneumococcal conjugate vaccine for infants and children

April 28, 2023
Market Access, Research and Development, Sales and Marketing Ear Nose & throat, FDA, Immunology, Pfizer, Vaccine, pneumococcal vaccine

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its PREVNAR 20 (20-valent pneumococcal conjugate vaccine) …

glsun-mall-9xmv81sz5fw-unsplash

Boehringer Ingelheim invests €350m in Europe’s largest biotech development centre

April 28, 2023
Manufacturing and Production

Boehringer Ingelheim (BI) have announced that it will invest €350m in a state-of-the-art Biologicals Development Centre (BDC) in Germany. It …

james-yarema-5tymgag0wro-unsplash_1

Daewoong Pharmaceutical and Vitalli Bio enter Global License Agreement for autoimmune disease candidate

April 28, 2023
Research and Development

South Korean Daewoong Pharmaceutical and US biotechnology company Vitalli Bio – a portfolio company of Aditum Bio – have announced …

huha-inc-ofvesgqrbjc-unsplash

Eli Lilly’s tirzepatide achieves 15.7% weight loss in adult patients

April 28, 2023
Research and Development

Eli Lilly has announced that tirzepatide (10mg and 15mg) achieved significant and superior weight loss compared to a placebo over …

First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study

April 27, 2023
Research and Development Avacta

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the …

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

April 27, 2023
Business Services CHMP, Cosentyx, Dermatology, Novartis

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European …

markus-spiske-dnbtfbnqlrc-unsplash_1

GSK’s RSV vaccine candidate gains positive EMA CHMP opinion

April 27, 2023
Medical Communications

GSK has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has shared a …

FDA approves first orally-administered faecal microbiota product for preventing serious gut infection

April 27, 2023
Medical Communications

The US Food and Drug Administration (FDA) has announced that it has approved the first orally-ingested faecal microbiota product for …

towfiqu-barbhuiya-hn2hqoalbck-unsplash_1

National Institutes of Health awards grant for gammaCore clinical trial for patients with opioid use disorders

April 27, 2023
Research and Development

Bioelectronic medicine and wellness company electroCore have announced that the National Institute on Drug Abuse (NIDA) part of the National …

anirudh-djo3injpaoe-unsplash_3

NICE recommends two CAR T treatments for blood cancers to the Cancer Drugs Fund

April 27, 2023
Medical Communications

The National Institute for Health and Care Excellence (NICE) has announced that it is recommending two personalised immunotherapy treatments to …

Aldena Therapeutics and Empa Awarded InnoSuisse Funding to Advance STAR Particles as a Novel Drug Delivery Technology for Dermatology

April 26, 2023
Business Services

Boston, Massachusetts, April 26, 2023 – Aldena Therapeutics Inc. (Aldena), a private biotech company pioneering siRNA-based therapies for dermatological indications, …

Epsilogen announces significant expansion of management team with three new senior hires

April 26, 2023
Business Services

London, 26 April 2023 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to …

FDA shares safety warning on amniotic fluid eyedrops

April 26, 2023
Medical Communications

The US Food and Drug Administration (FDA) has released a Public Safety Notification on eyedrops containing amniotic fluid currently being …

max-bender-w5bn80xghre-unsplash_1

FDA grants accelerated approval for QALSODY (tofersen) as ALS treatment

April 26, 2023
Medical Communications

Biogen has announced that the US Food and Drug Administration (FDA) has approved QALSODY (tofersen) 100mg/15ml injection for the treatment …

national-cancer-institute-l8twzt4ccvq-unsplash_1

UCB and Huma Therapeutics collaborate on digital health solution to improve rare disease management

April 26, 2023
Medical Communications

Digital health company Huma Therapeutics and biopharmaceutical company UCB are partnering to offer a digital technology solution to aid patients …

jair-lazaro-0lrjo37r6nk-unsplash

Abbott announces two FDA clearances for life support system

April 26, 2023
Medical Communications

US-based medical devices and healthcare company Abbott has announced two new clearances from the US Food and Drug Administration (FDA) …

MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases

April 25, 2023
Business Services

London, United Kingdom, April 25, 2023 — MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target …

PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

April 25, 2023
Business Services

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded …

The Gateway to Local Adoption Series

Latest content